Y-90 Radioembolization Studied for Locally Advanced HCC With Portal Vein Thrombosis

 

December 21, 2017—Online in Journal of Nuclear Medicine, Nadine Abouchaleh et al reported survival outcomes for advanced stage hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with yttrium-90 (Y-90) radioembolization. The investigators were led by Riad Salem, MD, at Northwestern University in Chicago, Illinois.

With approval of Northwestern's Institutional Review Board, the investigators searched their prospectively acquired database for patients treated with Y-90 between 2003 and 2017. The study included patients who had advanced stage HCC with tumor PVT. To minimize confounding effect, patients with metastases were excluded. Clinical and laboratory data were collected at baseline and 1-month after Y-90 treatment.

The investigators reported long-term survival outcomes stratified by Child-Pugh (CP) score. Overall survival was calculated using Kaplan-Meier analysis. Multivariate analysis was conducted using Cox proportion hazards. Additionally, the investigators conducted a subanalysis for patients with high alpha-fetoprotein (AFP) (> 100 ng/dL).

As summarized in Journal of Nuclear Medicine, 185 patients with PVT related to HCC received Y-90 treatment between 2003 and 2017. Seventy-four patients (40%) were CP-A, 51 (28%) were CP-B7, and 60 (32%) were ≥ CP-B8.

Median overall survival was 13.3 months for CP-A patients (95% confidence interval [CI], 8.7–15.7), 6.9 months for CP-B7 patients (95% CI, 5.3–10.1), and 3.9 months (95% CI, 2.9–5) for ≥ CP-B8 patients.

On multivariate analysis, the investigators found that baseline bilirubin, ascites, and AFP were more significant prognosticators. Of 123 patients with high AFP (> 100 ng/dL), 12 patients restored normal AFP levels (< 13 ng/dL) and exhibited median overall survival of 23.9 months (CI, 20.1–124.1).

The investigators concluded that Y-90 radioembolization can serve as a safe and effective treatment for advanced stage HCC patients with tumor PVT. The overall survival outcomes are affected by baseline liver function, tumor size, and AFP level, noted the investigators in Journal of Nuclear Medicine.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.